OLDWICK, N.J.–(BUSINESS WIRE)– #insurance–AM Best has downgraded the Financial Strength Rating (FSR) to B+ (Good) from B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) to “bbb-” (Good) from “bbb” (Good) of Hanover Fire & Casualty Insurance Company (Hanover) (King of Prussia, PA). Concurrently, AM Best has maintained the under review with negative implications status for these Credit Ratings (ratings).The ratings reflect Hanover’s balance sheet strength, which AM Best assesses as adequ
Month: September 2026
PORTLAND, Ore.–(BUSINESS WIRE)–PaintCare, the nonprofit organization that operates Oregon’s first-in-the-nation paint stewardship program, unveiled a new mural today in partnership with Portland Street Art Alliance (PSAA), a Portland-based nonprofit organization empowering local street artists. The project celebrates the state’s history of sustainability and paint stewardship by turning recycled paint into highly visible public art in Portland’s Buckman neighborhood. The mural was created by
NEWPORT BEACH, Calif.–(BUSINESS WIRE)– #FreedomAlliance–130 veterans will join members of SoCal’s sportfishing community for the ninth annual War Heroes on Water (WHOW) Presented by loanDepot.
SAN FRANCISCO–(BUSINESS WIRE)–AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of individuals affiliated with Astrana Health, Inc.’s subsidiary, Astrana Health Management, Inc. Astrana Health, Inc. is a California-based technology-powered healthcare company that operates as a Management Services Organization (MSO). On September 23, 2026, Astrana Health, Inc. disclosed to the Securities and Exchange Commission (“SEC”) that unauthorized ac
Orion Corporation: Acquisition of own shares during week 39, 2026
The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.
Orion Corporation’s shares have been acquired as follows:
| Date | Exchange transaction | Share trading code | Number of shares | Average price/ share (EUR)* | Total transaction value (EUR) | |||
| September 21, 2026 | Buy | ORNBV | 23,704 | 82.2724 | 1,950,184.97 | |||
| September 22, 2026 | Buy | ORNBV | 22,639 | 83.2528 | 1,884,760.14 | |||
| September 23, 2026 | Buy | ORNBV | 23,552 | 83.3016 | 1,961,919.28 | |||
| September 24, 2026 | Buy | ORNBV | 23,842 | 82.5790 | 1,968,848.52 | |||
| September 25, 2026 | Buy | ORNBV | 20,000 | 83.0657 | 1,661,314.00 | |||
| Total during week 39/2026 | Buy | ORNBV | 113,737 | 82.8844 | 9,427,023.00 | |||
*Average price rounded to four decimal places
After these acquisitions, Orion Corporation holds a total of 730,383 treasury shares which all are Class B shares.
On behalf of Orion Corporation
Danske Bank A/S, Finland Branch
Antti Väliaho, Jonathan Nyberg
For more information, please contact:
Tuukka Hirvonen, Head of Investor Relations
Orion Corporation
Tel. +358 10 426 2721, tuukka.hirvonen@orionpharma.com
Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.
Attachment

THE WOODLANDS, Texas–(BUSINESS WIRE)–Epsilyte, a leading North American producer of Expandable Polystyrene (EPS), will revise the previously announced increase of $0.06/lb. for all grades of EPS to $0.11/lb., effective October 1, 2026, or as contracts permit. These adjustments are the result of the continued increase in raw material costs. About Epsilyte Epsilyte is one of North America’s leading producers of advanced insulative materials. We are a company of scale focused on solving customer
Rexel to acquire GCG,
a leading specialty infrastructure platform in the US,
a key milestone on Rexel’s strategic roadmap
|
Rexel has entered into an agreement with Audax Private Equity (“Audax”) to acquire GCG, a leading US provider of specialty wire and cable, connectivity, power and engineered solutions for critical infrastructure applications. Headquartered in Chicago, Illinois, GCG operates 16 locations with approximately 950 employees and is expected to reach over $1.1 billion of revenue in 2026.
Compelling value-added service, exposed to high growth segments
GCG combines specialty distribution with a complete range of advanced services including engineering, custom assembly, product modification, kitting, testing and rapid fulfillment. A significant portion of its revenue is generated from proprietary offerings, while more than 75% incorporates value-added products or services. These capabilities allow GCG to participate further upstream in product design and specification, help customers reduce installation time and labor, and build more embedded customer relationships.
The acquisition will position Rexel at the center of several powerful mega trends reshaping the global economy and its electrification. More than 60% of GCG’s revenue is exposed to high growth segments including data centers, power/utilities infrastructure, grid modernization, communications, defense, utilities and other long-term growth markets where artificial intelligence, rising electricity demand and increasing technical complexity are driving sustained infrastructure investments.
Since 2019, GCG has delivered double-digit annual revenue growth and is expected to reach a c.11% EBITA margin in 2026, reflecting GCG’s exposure to structurally attractive end-markets, proprietary products, technical expertise and its value-add operating model.
Rexel’s Board of Directors has unanimously approved the acquisition of GCG.
Executing our value creating M&A strategy
This acquisition is fully aligned with Rexel’s strategy to accelerate further in its core geographies and is a strong driver of the Group’s accelerated sales growth.
Rexel also expects to generate meaningful cost synergies from GCG through scale, logistics optimization, insourcing and select efficiencies. In addition, the combination also creates significant commercial opportunities by bringing GCG’s engineered solutions and specialty distribution capabilities to Rexel’s broader customer base.
The transaction values GCG at an Enterprise Value of approximately $1.4 billion, corresponding to a <8x 2026e EBITDAaL multiple including anticipated run-rate synergies. This transaction respects all financial M&A criteria, including EPS accretion in year 1 and value creation by year 3.
Preserving our balance sheet
Rexel plans to finance GCG through a mix of existing cash on hand, and debt for c.€800 million.
The Group also intends to raise up to €500 million equity through an accelerated bookbuilding offering (subject to market conditions), to preserve its credit rating and maintain a net financial debt / EBITDAaL ratio around 2x from 2027 onwards.
As such, Rexel will maintain a balanced capital allocation strategy between a consistent dividend policy of at least 40% payout and a self-funded value creative acquisition strategy allowing the Group to continue delivering solid growth and returns to shareholders.
The transaction is expected to close by 2026 year-end, subject to customary regulatory approvals and closing conditions.
| Guillaume Texier, Chief Executive Officer of Rexel, commented: “The acquisition of GCG is an exciting and major step forward in Rexel’s strategy. It significantly expands our addressable market, strengthening our position in key, fast-growing segments. It moves Rexel into higher-value parts of the infrastructure value chain and creates a more complete offering across electrical power and digital connectivity. It is financially attractive, immediately accretive to adjusted earnings and to Rexel’s EBITA margin, with substantial additional value creation potential from synergies and commercial expansion. GCG also brings high-quality, talented teams with a strong reputation with customers, suppliers and partners, which will be key assets as we build a leading specialty infrastructure platform together. The acquisition of GCG, an exceptional platform combining strong growth, an attractive margin profile and differentiated capabilities is fully in line with Rexel’s Axelerate 28 strategy, which aims at shaping our portfolio towards more growth and more value-added, and is a significant step in the direction of achieving our mid-term objectives.” |
Advisors
Guggenheim Securities and Rothschild & Co served as financial advisors to Rexel and Sidley Austin LLP served as legal advisor. Solomon Partners and J.P. Morgan served as financial advisors to GCG, with Kirkland & Ellis and Fredrikson & Byron serving as legal counsel.
Analyst call and further information
Rexel will be hosting a call for analysts and investors at 6.15pm CET on September 25th, 2026. Participants are advised to join the call at least 10 minutes prior to the commencement of the call to register. Presentation materials will be available ahead of the call on the Rexel website. Please connect to the call via the following link: https://streamstudio.world-television.com/1524-2871-43792/en To dial in from France: +33 (0)1 70 91 87 04 (code: 596076) or from outside of France: +44 (0) 12 1281 8004 or +1 718 705 8796 (code: 596076)
About Rexel group
Rexel, worldwide expert in the multichannel professional distribution of products and services for the energy world, addresses three main markets: residential, non-residential, and industrial. The Group supports its residential, non-residential, and industrial customers by providing a tailored and scalable range of products and services in energy management for construction, renovation, production, and maintenance. Rexel operates through a network of 1,876 branches in 17 countries, with 26,306 employees. The Group’s sales were €19.4 billion in 2025.
Rexel is listed on the Eurolist market of Euronext Paris (compartment A, ticker RXL, ISIN code FR0010451203). It is included in the following indices: MSCI World, CAC Next 20, SBF 120, CAC Large 60, CAC SBT 1.5 NR, CAC AllTrade, CAC AllShares, FTSE EuroMid, and STOXX600. Rexel is also part of the following SRI indices: FTSE4Good, Dow Jones Sustainability Index Europe, Euronext Sustainable Europe 120 and S&P Global Sustainability Yearbook 2025, in recognition of its performance in terms of Corporate Social Responsibility (CSR).
For more information, visit www.rexel.com/en.
About GCG
GCG is a leading value-added provider of wire, cable, connectivity, and automation solutions serving diverse markets. With a comprehensive offering of premier brands and custom solutions, GCG is the preferred provider for original equipment manufacturers, contractors, installers, and other end users in attractive, mission critical markets. GCG generates over $1 billion in annual revenue via more than 16 facilities. GCG has cable assembly operations and product engineering capabilities to support unique customer needs and is proud to be a leading wire and cable provider to the U.S. Navy.
About Audax Private Equity
Headquartered in Boston, with offices in San Francisco, New York, London and Hong Kong, Audax Private Equity is a leading private equity platform focused on investing across the North American middle market. Our objective is to accelerate value creation through our Buy & Build strategy and the Audax Value Agenda™, a holistic framework that seeks to enable, create, and protect value across every stage of the investment lifecycle. As of July 2026, Audax Private Equity had approximately $20.1 billion of assets under management and, since inception in 1999, has invested in more than 180 platforms and more than 1,500 add-on acquisitions. For more information, visit www.audaxprivateequity.com or follow us on LinkedIn.
Contacts
Financial analysts/investors
| Ludovic Debailleux | +33 1 42 85 76 12 | ludovic.debailleux@rexel.com |
Press
| Taddeo : Pierre-Jean Le Mauff | +33 7 77 78 58 67 | Pierre-jean.lemauff@taddeo.fr |
Disclaimer
The Group is exposed to fluctuations in copper prices in connection with its distribution of cable products. Cables accounted for approximately 16% of the Group’s sales and copper accounts for approximately 60% of the composition of cables. This exposure is indirect since cable prices also reflect copper suppliers’ commercial policies and the competitive environment in the Group’s markets. Changes in copper prices have an estimated so-called “recurring” effect and an estimated so called “non-recurring” effect on the Group’s performance assessed as part of the monthly internal reporting process of the Rexel Group: i) the recurring effect related to the change in copper-based cable prices corresponds to the change in value of the copper part included in the sales price of cables from one period to another. This effect mainly relates to the Group’s sales; ii) the non-recurring effect related to the change in copper-based cable prices corresponds to the effect of copper price variations on the sales price of cables between the time they are purchased and the time they are sold, until all such inventory has been sold (direct effect on gross profit). Practically, the non-recurring effect on gross profit is determined by comparing the historical purchase price for copper-based cable and the supplier price effective at the date of the sale of the cables by the Rexel Group. Additionally, the non-recurring effect on current EBITA corresponds to the non-recurring effect on gross profit, which may be offset, when appropriate, by the non-recurring portion of changes in the distribution and administrative expenses.
The impact of these two effects is assessed for as much of the Group’s total cable sales as possible, over each period. Group procedures require that entities that do not have the information systems capable of such exhaustive calculations to estimate these effects based on a sample representing at least 70% of the sales in the period. The results are then extrapolated to all cables sold during the period for that entity. Considering the sales covered, the Rexel Group considers such estimates of the impact of the two effects to be reasonable.
This press release does not constitute or form any part of an offer to sell, exchange or purchase, or solicitation of an offer to buy or exchange, any securities in the United States, Australia, Canada or Japan or in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The distribution of this press release may, in certain states or jurisdictions, be restricted by local legislations. Persons into whose possession this press release comes are required to inform themselves about and to observe any such potential local restrictions. This announcement is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada or Japan.
Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of securities in the United States.
This document may contain statements of future expectations and other forward-looking statements. By their nature, they are subject to numerous risks and uncertainties, including those described in the Universal Registration Document registered with the French Autorité des Marchés Financiers (AMF) on March 10, 2026 under number D.26-0073. These forward-looking statements are not guarantees of Rexel’s future performance, Rexel’s actual results of operations, financial condition and liquidity as well as development of the industry in which Rexel operates may differ materially from those made in or suggested by the forward-looking statements contained in this release. The forward-looking statements contained in this communication speak only as of the date of this communication and Rexel does not undertake, unless required by law or regulation, to update any of the forward-looking statements after this date to conform such statements to actual results to reflect the occurrence of anticipated results or otherwise.
The market and industry data and forecasts included in this document were obtained from internal surveys, estimates, experts and studies, where appropriate, as well as external market research, publicly available information and industry publications. Rexel, its affiliates, directors, officers, advisors and employees have not independently verified the accuracy of any such market and industry data and forecasts and make no representations or warranties in relation thereto. Such data and forecasts are included herein for information purposes only.
This document includes only summary information and must be read in conjunction with Rexel’s Universal Registration Document registered with the AMF on March 10, 2026 under number D.26-0073, and the half-year financial report for the six month period ended June 30, 2026 which can be obtained from Rexel’s website (www.rexel.com) .
Attachment

LEOBENDORF, Autriche–(BUSINESS WIRE)–Croma-Pharma lance saypha® volume prime Lidocaine, un produit de comblement dermique à base d’acide hyaluronique réticulé qui remplace saypha® volume Lidocaine au sein de la gamme saypha® de l’entreprise. Ce nouveau produit offre aux médecins une solution davantage polyvalente, comprenant des indications élargies à la fois pour la volumisation de la zone médio-faciale et pour le traitement des sillons nasogéniens, toutes deux étayées par de solides données
MINNEAPOLIS, Sept. 25, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (the “Company,” “we,” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it will implement a 1-for-10 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern Time on September 29, 2026. The Reverse Stock Split was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on September 18, 2026, with the final ratio, within the range approved by stockholders, subsequently determined by the Company’s board of directors. The Reverse Stock Split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and to broaden investor interest.
The Company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on September 29, 2026 under the Company’s existing trading symbol “ONMD” with the new CUSIP number 68270C 202.
At the effective time of the Reverse Stock Split, every ten (10) shares of the Company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock without any change in the par value per share. The Reverse Split will reduce the number of shares of outstanding common stock from approximately 59,286,450 shares, the number of shares outstanding as of September 24, 2026, to approximately 5,928,645 shares of common stock. The total authorized number of shares will not be reduced. The Reverse Stock Split will also proportionately adjust the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity instruments, in each case in accordance with their terms.
No fractional shares will be issued in connection with the Reverse Stock Split. Any fractional shares of common stock resulting from the Reverse Stock Split will be rounded up to the nearest whole share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s relative interest in the Company’s equity securities, except for any adjustments for fractional shares.
Continental Stock Transfer & Trust Company is acting as the exchange agent and transfer agent for the Reverse Stock Split. Stockholders holding their shares electronically are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker or other nominee will have their positions adjusted to reflect the Reverse Stock Split, subject to such broker’s particular processes.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform is powered by Palantir Foundry and supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements may describe our future plans and expectations and are based on the current beliefs, expectations and assumptions of the Company. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of forward-looking statements in this press release include but are not limited to statements about the timing and implementation of the Reverse Stock Split and the commencement of trading of the Company’s post-split common stock, the impact of the Reverse Stock Split on the Company’s securityholders, the potential for the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the expected number of shares of common stock to be issued and outstanding following the Reverse Stock Split.
We urge you to consider those factors, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “SEC”), any subsequently filed quarterly reports on Form 10-Q as well as in other documents that may have been subsequently filed by the Company, from time to time, with the SEC, in evaluating our forward-looking statements. In addition, any forward-looking statements represent the Company’ views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements unless required by law.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION

LEOBENDORF, Austria–(BUSINESS WIRE)–Croma-Pharma presenta saypha® volume prime con lidocaina, un filler dermico a base di acido ialuronico reticolato che sostituisce saypha® volume con lidocaina all’interno del portafoglio di prodotti saypha® dell’azienda. Il nuovo prodotto offre ai medici una soluzione più versatile con indicazioni più ampie sia per la volumizzazione del terzo medio del viso che per le pieghe nasolabiali, supportate da solidi dati clinici.1,2 saypha® volume prime con lidocai
